It is with great pleasure to announce that Swiss HLG is welcoming our new board member Monika Baudler-Klein, joining us from our valued long term supporter Roche.
Monika holds a PhD in Biochemistry from University of Würzburg and has been in the pharmaceutical industry for more than 25 years working in various discovery, development, commercial and licensing roles with a focus on people and project leadership, portfolio management and strategy giving her a true end-to-end perspective on bringing transformative medicines to patients.
Before joining Roche in 2012, she served as Global Head of Pipeline Sourcing and Portfolio Management at Nycomed where she and her team drove an ambitious in-licensing strategy to complement the company’s portfolio. In her time in Roche, Monika initially focused on supporting the growing Neurology pipeline from a portfolio, commercial and in-licensing strategy perspective before taking on the leadership of the late stage Alzheimer’s portfolio as Life Cycle Leader Gantenerumab and Crenezumab.
A catalyst for building trustful relationships with internal and external stakeholders, she recently joined Roche’s Corporate Business Development as Executive Director Global Alliance & Asset Management leveraging her broad experience in skillfully managing partnerships with diverse external groups and organizations.
Monika adds: ¨I am thrilled to be joining the exceptional and highly experienced Swiss HLG Board and I look forward to making an impact on the active Swiss health care community by contributing my broad pharma expertise and by fostering productive partnerships and cross-industry collaboration.”
2023 © Swiss HLG | by evago.fr
Cookies settings
